Original language | English |
---|---|
Pages (from-to) | e5-e10 |
Journal | Biological Psychiatry |
Volume | 88 |
Issue number | 2 |
DOIs | |
State | Published - Jul 15 2020 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Biological Psychiatry, Vol. 88, No. 2, 15.07.2020, p. e5-e10.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Realizing the Clinical Potential of Computational Psychiatry
T2 - Report From the Banbury Center Meeting, February 2019
AU - Browning, Michael
AU - Carter, Cameron S.
AU - Chatham, Christopher
AU - Den Ouden, Hanneke
AU - Gillan, Claire M.
AU - Baker, Justin T.
AU - Chekroud, Adam M.
AU - Cools, Roshan
AU - Dayan, Peter
AU - Gold, James
AU - Goldstein, Rita Z.
AU - Hartley, Catherine A.
AU - Kepecs, Adam
AU - Lawson, Rebecca P.
AU - Mourao-Miranda, Janaina
AU - Phillips, Mary L.
AU - Pizzagalli, Diego A.
AU - Powers, Albert
AU - Rindskopf, David
AU - Roiser, Jonathan P.
AU - Schmack, Katharina
AU - Schiller, Daniela
AU - Sebold, Miriam
AU - Stephan, Klaas Enno
AU - Frank, Michael J.
AU - Huys, Quentin
AU - Paulus, Martin
N1 - Funding Information: This work was supported by the Medical Research Council Clinician Scientist Fellowship (Grant No. MR/N008103/1 [to MB]), National Institute for Health Research Oxford Health Biomedical Research Centre (MB), Max Planck Society (to PD), National Institutes of Health (Grant Nos. 1R01DA041528 , 1R01DA047851 , and 1R01AT010627 [to RZG]), National Institute on Drug Abuse Small Business Innovation Research Phase I subcontract to Soterix Medical (Grant No. 271201800035C [to RZG]), Wellcome Trust (Grant No. WT102845/Z/13/Z [to JM-M]), National Institute of Mental Health K23 Career Development Award (Grant No. K23 MH115252-01A1 [to AP]), Burroughs-Wellcome Fund Career Award for Medical Scientists (to AP), René and Susanne Braginsky Foundation (to KES), and National Institute of General Medical Sciences (Grant No. P20GM121312 [to MP]). The Banbury Center Meeting was funded by grants from the Society for Biological Psychiatry, William K. Warren Foundation , and Robert J. & Nancy D. Carney Institute for Brain Science at Brown University . Funding Information: This work was supported by the Medical Research Council Clinician Scientist Fellowship (Grant No. MR/N008103/1 [to MB]), National Institute for Health Research Oxford Health Biomedical Research Centre (MB), Max Planck Society (to PD), National Institutes of Health (Grant Nos. 1R01DA041528, 1R01DA047851, and 1R01AT010627 [to RZG]), National Institute on Drug Abuse Small Business Innovation Research Phase I subcontract to Soterix Medical (Grant No. 271201800035C [to RZG]), Wellcome Trust (Grant No. WT102845/Z/13/Z [to JM-M]), National Institute of Mental Health K23 Career Development Award (Grant No. K23 MH115252-01A1 [to AP]), Burroughs-Wellcome Fund Career Award for Medical Scientists (to AP), Ren? and Susanne Braginsky Foundation (to KES), and National Institute of General Medical Sciences (Grant No. P20GM121312 [to MP]). The Banbury Center Meeting was funded by grants from the Society for Biological Psychiatry, William K. Warren Foundation, and Robert J. & Nancy D. Carney Institute for Brain Science at Brown University. We thank John Krystal, M.D. Bruce Cuthbert, M.D. Anne Churchland, Ph.D. and Michele Ferrante, Ph.D. for invaluable discussion and advice. MB has received travel expenses from Lundbeck for attending conferences and acted as a consultant for Janssen Research and the Centre for Human Drug Research. CC is a full-time employee of Hoffman La Roche. HDO has acted as a consultant for Lundbeck Pharmaceuticals. JTB has received consulting fees from Pear Therapeutics, BlackThorn Therapeutics, Niraxx Therapeutics, and AbleTo, Inc. AMC holds equity in Spring Care, Inc. Fitbit, Inc. and UnitedHealthcare, Inc.; is lead inventor on three patent submissions relating to treatment for major depressive disorder (U.S. Patent and Trademark Office Docket No, Y0087.70116US00, U.S. Patent and Trademark Office provisional application 62/491,660, and USPTO provisional application 62/629,041); and has consulted for Fortress Biotech, Inc. on antidepressant drug development. JG receives royalty payments from the Brief Assessment of Cognition in Schizophrenia. Over the past 3 years, MLP has received an honorarium from Sunovion Pharmaceuticals. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Compass, Posit Science, and Takeda Pharmaceuticals and an honorarium from Alkermes for activities unrelated to the current article. JPR has acted as a consultant for Cambridge Cognition, Takeda, and GE Healthcare. MJF is a consultant for Hoffman La Roche. MP is an advisor to Spring Care, Inc. and he has received royalties for an article about methamphetamine in UpToDate. The other authors report no biomedical financial interests or potential conflicts of interest.
PY - 2020/7/15
Y1 - 2020/7/15
UR - http://www.scopus.com/inward/record.url?scp=85086574751&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2019.12.026
DO - 10.1016/j.biopsych.2019.12.026
M3 - Letter
C2 - 32113656
AN - SCOPUS:85086574751
SN - 0006-3223
VL - 88
SP - e5-e10
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 2
ER -